Rallybio Corporation (NASDAQ:RLYB) Receives $5.00 Consensus Target Price from Brokerages

Shares of Rallybio Corporation (NASDAQ:RLYB) have received a consensus recommendation of “Reduce” from the five research firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $40.00.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Rallybio in a research report on Monday, December 29th.

Institutional Investors Weigh In On Rallybio

Large investors have recently modified their holdings of the business. Citadel Advisors LLC grew its position in Rallybio by 576.1% during the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after purchasing an additional 373,821 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Rallybio by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after buying an additional 2,996 shares during the period. Finally, Susquehanna International Group LLP grew its holdings in shares of Rallybio by 485.9% during the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after buying an additional 113,031 shares during the last quarter. Hedge funds and other institutional investors own 90.34% of the company’s stock.

Rallybio Price Performance

RLYB stock opened at $4.70 on Thursday. Rallybio has a 1-year low of $1.76 and a 1-year high of $6.99. The business has a 50-day moving average price of $5.50 and a 200 day moving average price of $4.96. The company has a market capitalization of $24.82 million, a P/E ratio of -1.84 and a beta of -1.05.

Rallybio Company Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.